MK-677 vs Tesamorelin: How These GH Secretagogues Compare

The short answer: MK-677 and tesamorelin both raise growth hormone and IGF-1, but they are very different products. MK-677 is an oral ghrelin receptor agonist sold as a research chemical with no FDA approval for human use, while tesamorelin is an FDA-approved injectable GHRH analog prescribed for visceral fat reduction in adults with HIV-associated lipodystrophy. The right choice usually comes down to legal status, route of administration, and the specific goal.

What Is MK-677 (Ibutamoren)?

MK-677, also called ibutamoren or Nutrobal, is a non-peptide molecule that binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. It mimics ghrelin, the hunger hormone, which is why it drives GH release and also triggers a strong appetite increase.

Key facts about MK-677:

• Route: Oral, usually once daily.
• Half-life: Roughly 24 hours, producing fairly continuous GH and IGF-1 elevation rather than natural pulses.
• Research doses: Commonly listed at 10-25 mg per day, though no standard human dose exists because it is not an approved drug.
• FDA status: MK-677 is not FDA-approved for any human use in the United States.

MK-677 has no long-term human safety data. Short studies report increases in IGF-1, appetite, and fasting blood glucose, and users frequently describe water retention, lethargy, and intense hunger.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary and triggers GH release while preserving much of the body's natural pulsatile rhythm.

Key facts about tesamorelin:

• Route: Subcutaneous injection, once daily.
• Approved dose: Egrifta WR is dosed at 1.4 mg daily; the older Egrifta formulation used 2 mg daily.
• FDA status: Approved in 2010 and reformulated as Egrifta WR in 2019 for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
• Other research: Studied for nonalcoholic fatty liver disease and cognitive outcomes, but neither is an approved indication.

Tesamorelin is a prescription medication that requires a doctor's oversight. It is not approved for general weight loss, bodybuilding, or anti-aging.

MK-677 vs Tesamorelin: Head-to-Head Comparison

Feature	MK-677	Tesamorelin
Mechanism	Ghrelin receptor (GHS-R1a) agonist	GHRH receptor agonist
Route	Oral	Subcutaneous injection
FDA status	Not approved for human use	Approved (Egrifta WR) for HIV-associated lipodystrophy
Typical dose	10-25 mg daily in research settings	1.4 mg daily as prescribed
GH release pattern	Sustained and less pulsatile	Pulsatile, closer to natural rhythm
Appetite effect	Marked increase	Little to no increase
Best-documented use	Research on GH, IGF-1, and appetite	Visceral fat reduction in HIV lipodystrophy
Availability	Research chemical	Prescription only

Fat Loss and Body Composition

Tesamorelin is the only one of the two with an FDA-approved fat-loss indication, and its effect is specific: it reduces visceral adipose tissue rather than overall body weight. In clinical trials, adults with HIV-associated lipodystrophy lost roughly 15-20% of their visceral fat over 26 weeks, while subcutaneous fat changed little.

MK-677 has no comparable fat-loss evidence. Its main metabolic signal in studies is increased appetite, which often leads to higher calorie intake and weight gain rather than loss.

Many people researching fat loss also compare aod 9604 vs hgh, and some look at aod 9604 with tesamorelin to see whether a GH fragment adds anything to a GHRH analog. AOD-9604 is itself not FDA-approved, so those comparisons are about research interest rather than proven clinical results.

Side Effects and Safety Considerations

Side effect	MK-677	Tesamorelin
Increased appetite	Common and often strong	Uncommon
Water retention or edema	Common	Occasional
Fasting glucose rise	Reported; may reduce insulin sensitivity	Mild elevations possible
Joint or muscle pain	Reported	Common in trials
Injection site reactions	Not applicable	Common
IGF-1 elevation	Yes, sustained	Yes, dose-dependent

Both compounds raise IGF-1, and chronically elevated IGF-1 is a legitimate concern that doctors monitor with bloodwork. Neither should be used by people with active cancer, uncontrolled diabetes, or pituitary disease without specialist guidance.

MK-677 can cause meaningful increases in fasting blood glucose and insulin resistance in some users, along with fluid retention, joint stiffness, and hunger. Tesamorelin's most common complaints are injection site reactions, joint pain, and mild fluid retention.

Other Options People Compare

MK-677 and tesamorelin are rarely the only two options under consideration. Researchers exploring growth hormone secretagogues often weigh cjc-1295 ipamorelin vs tesamorelin to decide between a GHRH and GHRP combination or a single GHRH analog.

People asking about fat metabolism specifically often search sermorelin vs aod 9604, since one targets GH release while the other targets fat breakdown. For scale weight, prescription incretin drugs are a different category entirely, and the ongoing debate over cagrilintide vs retatrutide vs tirzepatide reflects how much more potent those agents are even though they do not act on the GH/IGF-1 axis.

Bottom Line

• Tesamorelin is FDA-approved for one narrow use: visceral fat reduction in adults with HIV-associated lipodystrophy.
• MK-677 is not approved by the FDA for any human use and is sold as a research chemical with unverified purity.
• Neither compound is a proven general-purpose fat-loss or muscle-building drug.
• Both can affect blood sugar, fluid balance, and IGF-1, so medical supervision matters.
• Talk with a licensed healthcare professional before using either, and never replace prescribed treatment with a research chemical.

COMMON QUESTIONS

Frequently Asked Questions

Is MK-677 or tesamorelin better for fat loss?

Tesamorelin is the better-documented option because it is FDA-approved to reduce visceral abdominal fat in adults with HIV-associated lipodystrophy, with trials showing roughly 15-20% visceral fat loss over 26 weeks. MK-677 has no approved fat-loss indication and tends to increase appetite, which can lead to weight gain rather than loss.

Is tesamorelin FDA-approved?

Yes. Tesamorelin is approved as Egrifta WR for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, bodybuilding, or anti-aging, and it requires a prescription.

Can you stack MK-677 with tesamorelin?

There is no clinical research supporting that combination, and stacking two compounds that both raise GH and IGF-1 increases the risk of fluid retention, blood sugar problems, and chronically elevated IGF-1. Anyone considering it should speak with a healthcare professional rather than self-experiment with a research chemical.